Results for tag: "Thromboembolism Drug"

The Thromboembolism Drug market is a subset of the Cardiovascular Drugs market, which focuses on the prevention and treatment of thromboembolic diseases. These drugs are used to reduce the risk of blood clots forming in the arteries and veins, which can lead to serious health complications such as stroke, heart attack, and pulmonary embolism. Thromboembolism drugs are typically anticoagulants, which work by preventing the formation of clots, or thrombolytics, which work by breaking down existing clots. The Thromboembolism Drug market is highly competitive, with a range of products available from both generic and branded manufacturers. Commonly prescribed drugs include warfarin, heparin, and low molecular weight heparins. Newer drugs such as direct oral anticoagulants (DOACs) are also becoming increasingly popular. Some of the major companies in the Thromboembolism Drug market include Pfizer, Sanofi, Bayer, Bristol-Myers Squibb, and Boehringer Ingelheim. Show Less Read more